In Memoriam: Carol Kasper, MD
The National Bleeding Disorders Foundation was saddened to learn of the passing of Carol Kasper, MD, a pioneer in the treatment of bleeding disorders, who died on July 8, 2025.Dr. Kasper received her undergraduate degree from the University of…
Access New Healthcare Provider Education on Bone & Mental Health in Women with Bleeding Disorders
NBDF is delighted to share our latest Collaborative Learning Exchange (CLE), “Assessing the Wellbeing of Women with Bleeding Disorders: Focus on Bone and Mental Health.” Recorded live and virtually on June 25th, …
NFRC Features Resources Supporting Joint Heath in People with Bleeding Disorders
Summer is now in full swing, with the sunny promise of more opportunities to get outside and be active. With that in mind, the Neil Frick Resource Center (NFRC) is highlighting resources to encourage better joint health in people with hemophilia and…
Pfizer Announces Phase 3 Trial Results for Hemophilia/Inhibitor Therapy
Pfizer recently announced results from a clinical study which is currently evaluating HYMPAVZI™ (marstacimab-hncq) for adults and adolescents living with hemophilia A or B with inhibitors. The therapy was approved by the U.S. Food…
Literature Review Reaffirms Clinical Relevance of Von Willebrand Disease Guideline
In early 2021, a pair of much needed evidence-based guidelines on the diagnoses and management of von Willebrand disease (VWD) were issued by an international group of organizations eager to build consensus on VWD screening and…
New Trial Data Suggests Oral ITP Therapy Effective in Children and Adolescents
Newly published findings suggest positive results from a late-stage clinical trial on a much-needed treatment option for young people with persistent or chronic primary immune thrombocytopenia (ITP).ITP is a rare autoimmune disorder that causes a…
Identification of a Potential Novel Role for Factor IX Using a Zebrafish Model
Pathway to Cures Welcomes Dr. Sylvia Fong
Pathway to Cures, the venture philanthropy fund of the National Bleeding Disorders Foundation, is delighted to name Sylvia Fong, PhD as a member of its Scientific Advisory Group. Dr. Fong joins Katherine High, MD; Haiyan Jiang, PhD;…
National Research Blueprint Becomes Bleeding Disorders Research Collaborative
The National Bleeding Disorders Foundation’s (NBDF) National Research Blueprint (NRB), launched in 2020, has a new name: the Bleeding Disorders Research Collaborative.  An article published in Blood…
Be Biopharma Announces First Hemophilia Patient Dosed with New Cell Therapy
Clinical stage biotechnology Be Biopharma, Inc. recently announced that the first hemophilia B patient has been treated with a single intraveneous dose of their investigational cell therapy, BE-101. The ongoing BeCoMe-9 Phase 1/2 study is evaluating…